Doug Fisher
Executive in Residence & Partner @ InterWest Partners
San Francisco, United States
Doug Fisher is a Series B investor at InterWest Partners in San Francisco focused on Health Care and Biotechnology. Dr. Doug Fisher joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic, and medical device investments. He is a board member of Cardiac Dimensions, Gynesonics, Obalon Therapeutics, PMV Pharma, QuatRx, Sera Prognostics and USDS. Doug also is actively involved in InterWest's investments in IntegratedDiagnostics and Invuity.Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix. Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in new disease areas for Remicade.Doug received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Doug Fisher invests in
Stages Doug Fisher invests in
Countries Doug Fisher invests in
Investment Focus
Industry
- Health Care 5 (45%)
- Biotechnology 4 (36%)
- Medical 3 (27%)
- Hospital 2 (18%)
- Therapeutics 2 (18%)
Stage
- Series B 2 (18%)
- Series C 2 (18%)
- Private Equity 2 (18%)
- Series A 1 (9%)
- Series D 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | |
|
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $147.5M / Series B / May 09, 2022 | |
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $75M / Private Equity / Jan 03, 2018 | |
Integrated Diagnostics
|
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The companyplans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules. | $6.1M / Series C / Dec 28, 2016 | |
Obalon Therapeutics
|
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronicdisease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.It was founded in 2008. | $15.8M / Series E / May 01, 2016 | |
|
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $43M / Jul 22, 2015 | |
Invuity
|
Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques.Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California. | $22.9M / Private Equity / Feb 13, 2015 | |
|
Obalon Therapeutics
|
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize the treatment of chronicdisease. As a company, they believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.It was founded in 2008. | $20M / Series D / Jan 14, 2015 | |
Sera Prognostics
|
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $20M / Series B / Jan 07, 2015 | |
|
Gynesonics
|
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. | $28.4M / Debt Financing / Jul 10, 2014 | |
| See all 11 investments → | |||
Co-Investors
About InterWest Partners
InterWest invests an average of about $7 - 15 million over the span of their involvement with each company in their portfolio. They invest in companies through the full range of venture investment stages, and investments may be staged over several rounds of financing. Although they generally begin their involvement in the early stages of acompany's development, they pursue attractive opportunities based on their individual merits rather than their investment stage.
InterWest Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Doug Fisher
Executive in Residence & Partner
|
|||
Arnie Oronsky
Managing Director
|
|||
Charline Gauthier
Executive-in-Residence
|
|||
Karen Wilson
CFO
|
|||
Katie Passalacqua
Controller
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Doug Fisher invest in?
Doug Fisher invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Doug Fisher last invest?
The most recent investment recorded for Doug Fisher closed in Nov 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
